research article review on removal of BET from plasma protein through DEAE resin

Removing bovine endogenous retrovirus (BERV) or Bovine exogenous retrovirus (BERV) from plasma protein is important to avoid contamination of biological products. One common method for removing BET from plasma protein is through DEAE (Diethylaminoethyl) resin anion-exchange chromatography.

A study by Tsai et al. (2013) titled "Removal of Bovine Exogenous Retrovirus from Human Plasma-Derived Products Using DEAE Anion-Exchange Chromatography" published in the Journal of Virological Methods, describes the use of DEAE resin anion-exchange chromatography to effectively remove BET from human plasma-derived products such as albumin, immunoglobulin, and coagulation factor IX. The study found that DEAE resin anion-exchange chromatography was able to effectively remove BET proteins while maintaining the activity and purity of the plasma proteins.

Another study by Wang et al. (2015) titled "Removal of bovine endogenous retrovirus from human plasma-derived protein using DEAE anion-exchange chromatography" published in the Journal of Chromatography B, describes the use of DEAE resin anion-exchange chromatography to remove BET from human plasma-derived protein such as immunoglobulin. The study found that DEAE resin anion-exchange chromatography was able to effectively remove BET proteins while maintaining the activity and purity of the plasma protein.

Both studies show that DEAE resin anion-exchange chromatography is a viable method for removing BET from plasma protein while preserving the activity and purity of the protein. However, it is important to note that specific conditions such as buffer pH, salt concentration, and column loading need to be optimized according to the plasma protein sample. Additionally, it may be necessary to use additional chromatography techniques, such as size-exclusion or affinity chromatography, to achieve optimal BET removal from the plasma protein.

Comments

Post a Comment

Popular posts from this blog

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

Image
MOA                  of   Aminoglycoside             Antibiotics Aminoglycosides exert their bactericidal effect by inhibiting protein synthesis in bacteria and compromising the structure of the bacterial cell wall . Aminoglycoside Antibiotics Aminoglycoside antibiotics are used to treat serious infections caused by gram-negative bacteria . Some commonly used aminoglycosides include: amikacin (Amikin®); apramycin; capreomycin; gentamicin (Garamycin®); kanamycin (Kantrex®); neomycin (Mycifradin®); netilmicin (Netromycin®); paromomycin (Humatin®); streptomycin; tobramycin (TOBI Solution®, TobraDex®, Nebcin®) Mode of Action Although aminoglycosides stop bacteria from making proteins, it is uncertain whether this is the action that results in bacterial cell death.     Disruption of Protein Synthesis A minoglyco s i d e s b i n d to the b a c t er i al 3 0 S r i b o s o mal s ubunit. R i b o s om e s are the p ro t e i n
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th
Read more